GUJTHEM · NSE
Not in active coverage. Cited reporting has mentioned Gujarat Themis Biosyn, the record of those mentions is below. Your interest is logged; coverage expands by demand.
Gujarat Themis Biosyn Limited completed the acquisition of MicroBiopharm Japan Co., Ltd. for ¥21.5 billion (Rs 1,300 crore).
Gujarat Themis Biosyn has completed the acquisition of 100 per cent equity shareholding in MicroBiopharm Japan Co., Ltd. for a total consideration of JPY 21.5 billion.
Gujarat Themis Biosyn announced the completion of the acquisition of 100% equity shareholding in MicroBiopharm Japan Co. (MBJ), Japan, through Themis Biosyn Japan, a wholly owned subsidiary incorporated in Japan.
Gujarat Themis Biosyn Ltd received shareholder approval for a qualified institutional placement and reported Q1 FY27 operational income of ₹43.79 crore with net profit of ₹11.07 crore, a 22% year-on-year increase.
This page lists where cited reporting has mentioned Gujarat Themis Biosyn. It is not the full dossier: developments here are single mentions, not corroborated records. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.